1
|
Foreman AL, Warth B, Hessel EVS, Price EJ, Schymanski EL, Cantelli G, Parkinson H, Hecht H, Klánová J, Vlaanderen J, Hilscherova K, Vrijheid M, Vineis P, Araujo R, Barouki R, Vermeulen R, Lanone S, Brunak S, Sebert S, Karjalainen T. Adopting Mechanistic Molecular Biology Approaches in Exposome Research for Causal Understanding. Environ Sci Technol 2024; 58:7256-7269. [PMID: 38641325 DOI: 10.1021/acs.est.3c07961] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 04/21/2024]
Abstract
Through investigating the combined impact of the environmental exposures experienced by an individual throughout their lifetime, exposome research provides opportunities to understand and mitigate negative health outcomes. While current exposome research is driven by epidemiological studies that identify associations between exposures and effects, new frameworks integrating more substantial population-level metadata, including electronic health and administrative records, will shed further light on characterizing environmental exposure risks. Molecular biology offers methods and concepts to study the biological and health impacts of exposomes in experimental and computational systems. Of particular importance is the growing use of omics readouts in epidemiological and clinical studies. This paper calls for the adoption of mechanistic molecular biology approaches in exposome research as an essential step in understanding the genotype and exposure interactions underlying human phenotypes. A series of recommendations are presented to make the necessary and appropriate steps to move from exposure association to causation, with a huge potential to inform precision medicine and population health. This includes establishing hypothesis-driven laboratory testing within the exposome field, supported by appropriate methods to read across from model systems research to human.
Collapse
Affiliation(s)
- Amy L Foreman
- European Molecular Biology Laboratory & European Bioinformatics Institute (EMBL-EBI), Wellcome Trust Genome Campus, Hinxton CB10 1SD, U.K
| | - Benedikt Warth
- Department of Food Chemistry and Toxicology, University of Vienna, 1090 Vienna, Austria
| | - Ellen V S Hessel
- National Institute for Public Health and the Environment (RIVM), Antonie van Leeuwenhoeklaan 9, 3721 MA Bilthoven, The Netherlands
| | - Elliott J Price
- RECETOX, Faculty of Science, Masaryk University, Kotlarska 2, Brno 60200, Czech Republic
| | - Emma L Schymanski
- Luxembourg Centre for Systems Biomedicine, University of Luxembourg, 6 avenue du Swing, L-4367 Belvaux, Luxembourg
| | - Gaia Cantelli
- European Molecular Biology Laboratory & European Bioinformatics Institute (EMBL-EBI), Wellcome Trust Genome Campus, Hinxton CB10 1SD, U.K
| | - Helen Parkinson
- European Molecular Biology Laboratory & European Bioinformatics Institute (EMBL-EBI), Wellcome Trust Genome Campus, Hinxton CB10 1SD, U.K
| | - Helge Hecht
- RECETOX, Faculty of Science, Masaryk University, Kotlarska 2, Brno 60200, Czech Republic
| | - Jana Klánová
- RECETOX, Faculty of Science, Masaryk University, Kotlarska 2, Brno 60200, Czech Republic
| | - Jelle Vlaanderen
- Institute for Risk Assessment Sciences, Division of Environmental Epidemiology, Utrecht University, Heidelberglaan 8 3584 CS Utrecht, The Netherlands
| | - Klara Hilscherova
- RECETOX, Faculty of Science, Masaryk University, Kotlarska 2, Brno 60200, Czech Republic
| | - Martine Vrijheid
- Institute for Global Health (ISGlobal), Barcelona Biomedical Research Park (PRBB), Doctor Aiguader, 88, 08003 Barcelona, Spain
- Universitat Pompeu Fabra, Carrer de la Mercè, 12, Ciutat Vella, 08002 Barcelona, Spain
- Centro de Investigación Biomédica en Red Epidemiología y Salud Pública (CIBERESP), Av. Monforte de Lemos, 3-5. Pebellón 11, Planta 0, 28029 Madrid, Spain
| | - Paolo Vineis
- Department of Epidemiology and Biostatistics, School of Public Health, Imperial College, London SW7 2AZ, U.K
| | - Rita Araujo
- European Commission, DG Research and Innovation, Sq. Frère-Orban 8, 1000 Bruxelles, Belgium
| | | | - Roel Vermeulen
- Institute for Risk Assessment Sciences, Division of Environmental Epidemiology, Utrecht University, Heidelberglaan 8 3584 CS Utrecht, The Netherlands
| | - Sophie Lanone
- Univ Paris Est Creteil, INSERM, IMRB, F-94010 Creteil, France
| | - Søren Brunak
- Novo Nordisk Foundation Center for Protein Research, University of Copenhagen, Copenhagen, Blegdamsvej 3B, 2200 København, Denmark
| | - Sylvain Sebert
- Research Unit of Population Health, University of Oulu, P.O. Box 8000, FI-90014 Oulu, Finland
| | - Tuomo Karjalainen
- European Commission, DG Research and Innovation, Sq. Frère-Orban 8, 1000 Bruxelles, Belgium
| |
Collapse
|
2
|
Collins EMS, Hessel EVS, Hughes S. How neurobehavior and brain development in alternative whole-organism models can contribute to prediction of developmental neurotoxicity. Neurotoxicology 2024; 102:48-57. [PMID: 38552718 DOI: 10.1016/j.neuro.2024.03.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/22/2023] [Revised: 03/01/2024] [Accepted: 03/23/2024] [Indexed: 04/12/2024]
Abstract
Developmental neurotoxicity (DNT) is not routinely evaluated in chemical risk assessment because current test paradigms for DNT require the use of mammalian models which are ethically controversial, expensive, and resource demanding. Consequently, efforts have focused on revolutionizing DNT testing through affordable novel alternative methods for risk assessment. The goal is to develop a DNT in vitro test battery amenable to high-throughput screening (HTS). Currently, the DNT in vitro test battery consists primarily of human cell-based assays because of their immediate relevance to human health. However, such cell-based assays alone are unable to capture the complexity of a developing nervous system. Whole organismal systems that qualify as 3 R (Replace, Reduce and Refine) models are urgently needed to complement cell-based DNT testing. These models can provide the necessary organismal context and be used to explore the impact of chemicals on brain function by linking molecular and/or cellular changes to behavioural readouts. The nematode Caenorhabditis elegans, the planarian Dugesia japonica, and embryos of the zebrafish Danio rerio are all suited to low-cost HTS and each has unique strengths for DNT testing. Here, we review the strengths and the complementarity of these organisms in a novel, integrative context and highlight how they can augment current cell-based assays for more comprehensive and robust DNT screening of chemicals. Considering the limitations of all in vitro test systems, we discuss how a smart combinatory use of these systems will contribute to a better human relevant risk assessment of chemicals that considers the complexity of the developing brain.
Collapse
Affiliation(s)
- Eva-Maria S Collins
- Swarthmore College, Biology, 500 College Avenue, Swarthmore, PA 19081, USA; Department of Neuroscience, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; Center of Excellence in Environmental Toxicology, University of Pennsylvania, Philadelphia, PA, USA.
| | - Ellen V S Hessel
- Centre for Health Protection, National Institute for Public Health and the Environment (RIVM), Antonie van Leeuwenhoeklaan 9, Bilthoven, 3721 MA, the Netherlands
| | - Samantha Hughes
- Department of Environmental Health and Toxicology, A-LIFE, Vrije Universiteit Amsterdam, de Boelelaan 1085, Amsterdam, 1081 HV, the Netherlands.
| |
Collapse
|
3
|
Nijboer TCW, Hessel EVS, van Haaften GW, van Zandvoort MJ, van der Spek PJ, Troelstra C, de Kovel CGF, Koeleman BPC, van der Zwaag B, Brilstra EH, Burbach JPH. Identification of candidate genes for developmental colour agnosia in a single unique family. PLoS One 2023; 18:e0290013. [PMID: 37672513 PMCID: PMC10482254 DOI: 10.1371/journal.pone.0290013] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/30/2023] [Accepted: 07/31/2023] [Indexed: 09/08/2023] Open
Abstract
Colour agnosia is a disorder that impairs colour knowledge (naming, recognition) despite intact colour perception. Previously, we have identified the first and only-known family with hereditary developmental colour agnosia. The aim of the current study was to explore genomic regions and candidate genes that potentially cause this trait in this family. For three family members with developmental colour agnosia and three unaffected family members CGH-array analysis and exome sequencing was performed, and linkage analysis was carried out using DominantMapper, resulting in the identification of 19 cosegregating chromosomal regions. Whole exome sequencing resulted in 11 rare coding variants present in all affected family members with developmental colour agnosia and absent in unaffected members. These variants affected genes that have been implicated in neural processes and functions (CACNA2D4, DDX25, GRINA, MYO15A) or that have an indirect link to brain function, development or disease (MAML2, STAU1, TMED3, RABEPK), and a remaining group lacking brain expression or involved in non-neural traits (DEPDC7, OR1J1, OR8D4). Although this is an explorative study, the small set of candidate genes that could serve as a starting point for unravelling mechanisms of higher level cognitive functions and cortical specialization, and disorders therein such as developmental colour agnosia.
Collapse
Affiliation(s)
- Tanja C. W. Nijboer
- UMCU Brain Center and Center of Excellence for Rehabilitation Medicine, University Medical Center Utrecht and De Hoogstraat Rehabilitation, Utrecht, The Netherlands
- Department of Experimental Psychology and Helmholtz Institute, Utrecht University, Utrecht, The Netherlands
| | - Ellen V. S. Hessel
- UMCU Brain Center and Center of Excellence for Rehabilitation Medicine, University Medical Center Utrecht and De Hoogstraat Rehabilitation, Utrecht, The Netherlands
- Department of Biomedical Genetics, University Medical Center Utrecht, Utrecht, The Netherlands
| | - Gijs W. van Haaften
- Department of Biomedical Genetics, University Medical Center Utrecht, Utrecht, The Netherlands
| | - Martine J. van Zandvoort
- Department of Experimental Psychology and Helmholtz Institute, Utrecht University, Utrecht, The Netherlands
| | - Peter J. van der Spek
- Department of Pathology, Erasmus Medical Center Rotterdam, Rotterdam, the Netherlands
| | - Christine Troelstra
- Department of Pathology, Erasmus Medical Center Rotterdam, Rotterdam, the Netherlands
| | - Carolien G. F. de Kovel
- Department of Biomedical Genetics, University Medical Center Utrecht, Utrecht, The Netherlands
| | - Bobby P. C. Koeleman
- Department of Biomedical Genetics, University Medical Center Utrecht, Utrecht, The Netherlands
| | - Bert van der Zwaag
- Department of Biomedical Genetics, University Medical Center Utrecht, Utrecht, The Netherlands
| | - Eva H. Brilstra
- Department of Biomedical Genetics, University Medical Center Utrecht, Utrecht, The Netherlands
| | - J. Peter H. Burbach
- UMCU Brain Center, Department of Translational Neuroscience, University Medical Center Utrecht, Utrecht, the Netherlands
| |
Collapse
|
4
|
de Leeuw VC, van Oostrom CTM, Zwart EP, Heusinkveld HJ, Hessel EVS. Prolonged Differentiation of Neuron-Astrocyte Co-Cultures Results in Emergence of Dopaminergic Neurons. Int J Mol Sci 2023; 24:ijms24043608. [PMID: 36835019 PMCID: PMC9959280 DOI: 10.3390/ijms24043608] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/21/2022] [Revised: 02/03/2023] [Accepted: 02/07/2023] [Indexed: 02/15/2023] Open
Abstract
Dopamine is present in a subgroup of neurons that are vital for normal brain functioning. Disruption of the dopaminergic system, e.g., by chemical compounds, contributes to the development of Parkinson's disease and potentially some neurodevelopmental disorders. Current test guidelines for chemical safety assessment do not include specific endpoints for dopamine disruption. Therefore, there is a need for the human-relevant assessment of (developmental) neurotoxicity related to dopamine disruption. The aim of this study was to determine the biological domain related to dopaminergic neurons of a human stem cell-based in vitro test, the human neural progenitor test (hNPT). Neural progenitor cells were differentiated in a neuron-astrocyte co-culture for 70 days, and dopamine-related gene and protein expression was investigated. Expression of genes specific for dopaminergic differentiation and functioning, such as LMX1B, NURR1, TH, SLC6A3, and KCNJ6, were increasing by day 14. From day 42, a network of neurons expressing the catecholamine marker TH and the dopaminergic markers VMAT2 and DAT was present. These results confirm stable gene and protein expression of dopaminergic markers in hNPT. Further characterization and chemical testing are needed to investigate if the model might be relevant in a testing strategy to test the neurotoxicity of the dopaminergic system.
Collapse
|
5
|
de Leeuw VC, van Oostrom CTM, Wackers PFK, Pennings JLA, Hodemaekers HM, Piersma AH, Hessel EVS. Neuronal differentiation pathways and compound-induced developmental neurotoxicity in the human neural progenitor cell test (hNPT) revealed by RNA-seq. Chemosphere 2022; 304:135298. [PMID: 35700809 PMCID: PMC9247748 DOI: 10.1016/j.chemosphere.2022.135298] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/18/2022] [Revised: 05/30/2022] [Accepted: 06/08/2022] [Indexed: 05/27/2023]
Abstract
There is an increased awareness that the use of animals for compound-induced developmental neurotoxicity (DNT) testing has limitations. Animal-free innovations, especially the ones based on human stem cell-based models are pivotal in studying DNT since they can mimic processes relevant to human brain development. Here we present the human neural progenitor test (hNPT), a 10-day protocol in which neural progenitor cells differentiate into a neuron-astrocyte co-culture. The study aimed to characterise differentiation over time and to find neurodevelopmental processes sensitive to compound exposure using transcriptomics. 3992 genes regulated in unexposed control cultures (p ≤ 0.001, log2FC ≥ 1) showed Gene Ontology (GO-) term enrichment for neuronal and glial differentiation, neurite extension, synaptogenesis, and synaptic transmission. Exposure to known or suspected DNT compounds (acrylamide, chlorpyrifos, fluoxetine, methyl mercury, or valproic acid) at concentrations resulting in 95% cell viability each regulated unique combinations of GO-terms relating to neural progenitor proliferation, neuronal and glial differentiation, axon development, synaptogenesis, synaptic transmission, and apoptosis. Investigation of the GO-terms 'neuron apoptotic process' and 'axon development' revealed common genes that were responsive across compounds, and might be used as biomarkers for DNT. The GO-term 'synaptic signalling', on the contrary, whilst also responsive to all compounds tested, showed little overlap in gene expression regulation patterns between the conditions. This GO-term may articulate compound-specific effects that may be relevant for revealing differences in mechanism of toxicity. Given its focus on neural progenitor cell to mature multilineage neuronal cell maturation and its detailed molecular readout based on gene expression analysis, hNPT might have added value as a tool for neurodevelopmental toxicity testing in vitro. Further assessment of DNT-specific biomarkers that represent these processes needs further studies.
Collapse
Affiliation(s)
- Victoria C de Leeuw
- Centre for Health Protection, National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands; Institute for Risk Assessment Sciences (IRAS), Utrecht University, Utrecht, the Netherlands.
| | - Conny T M van Oostrom
- Centre for Health Protection, National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands
| | - Paul F K Wackers
- Centre for Health Protection, National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands
| | - Jeroen L A Pennings
- Centre for Health Protection, National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands
| | - Hennie M Hodemaekers
- Centre for Health Protection, National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands
| | - Aldert H Piersma
- Centre for Health Protection, National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands; Institute for Risk Assessment Sciences (IRAS), Utrecht University, Utrecht, the Netherlands
| | - Ellen V S Hessel
- Centre for Health Protection, National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands
| |
Collapse
|
6
|
Vrijheid M, Basagaña X, Gonzalez JR, Jaddoe VWV, Jensen G, Keun HC, McEachan RRC, Porcel J, Siroux V, Swertz MA, Thomsen C, Aasvang GM, Andrušaitytė S, Angeli K, Avraam D, Ballester F, Burton P, Bustamante M, Casas M, Chatzi L, Chevrier C, Cingotti N, Conti D, Crépet A, Dadvand P, Duijts L, van Enckevort E, Esplugues A, Fossati S, Garlantezec R, Gómez Roig MD, Grazuleviciene R, Gützkow KB, Guxens M, Haakma S, Hessel EVS, Hoyles L, Hyde E, Klanova J, van Klaveren JD, Kortenkamp A, Le Brusquet L, Leenen I, Lertxundi A, Lertxundi N, Lionis C, Llop S, Lopez-Espinosa MJ, Lyon-Caen S, Maitre L, Mason D, Mathy S, Mazarico E, Nawrot T, Nieuwenhuijsen M, Ortiz R, Pedersen M, Perelló J, Pérez-Cruz M, Philippat C, Piler P, Pizzi C, Quentin J, Richiardi L, Rodriguez A, Roumeliotaki T, Sabin Capote JM, Santiago L, Santos S, Siskos AP, Strandberg-Larsen K, Stratakis N, Sunyer J, Tenenhaus A, Vafeiadi M, Wilson RC, Wright J, Yang T, Slama R. Advancing tools for human early lifecourse exposome research and translation (ATHLETE): Project overview. Environ Epidemiol 2021; 5:e166. [PMID: 34934888 PMCID: PMC8683140 DOI: 10.1097/ee9.0000000000000166] [Citation(s) in RCA: 12] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/26/2020] [Accepted: 06/28/2021] [Indexed: 11/26/2022] Open
Abstract
Early life stages are vulnerable to environmental hazards and present important windows of opportunity for lifelong disease prevention. This makes early life a relevant starting point for exposome studies. The Advancing Tools for Human Early Lifecourse Exposome Research and Translation (ATHLETE) project aims to develop a toolbox of exposome tools and a Europe-wide exposome cohort that will be used to systematically quantify the effects of a wide range of community- and individual-level environmental risk factors on mental, cardiometabolic, and respiratory health outcomes and associated biological pathways, longitudinally from early pregnancy through to adolescence. Exposome tool and data development include as follows: (1) a findable, accessible, interoperable, reusable (FAIR) data infrastructure for early life exposome cohort data, including 16 prospective birth cohorts in 11 European countries; (2) targeted and nontargeted approaches to measure a wide range of environmental exposures (urban, chemical, physical, behavioral, social); (3) advanced statistical and toxicological strategies to analyze complex multidimensional exposome data; (4) estimation of associations between the exposome and early organ development, health trajectories, and biological (metagenomic, metabolomic, epigenetic, aging, and stress) pathways; (5) intervention strategies to improve early life urban and chemical exposomes, co-produced with local communities; and (6) child health impacts and associated costs related to the exposome. Data, tools, and results will be assembled in an openly accessible toolbox, which will provide great opportunities for researchers, policymakers, and other stakeholders, beyond the duration of the project. ATHLETE's results will help to better understand and prevent health damage from environmental exposures and their mixtures from the earliest parts of the life course onward.
Collapse
Affiliation(s)
- Martine Vrijheid
- ISGlobal, Barcelona, Spain
- Spanish Consortium for Research on Epidemiology and Public Health (CIBERESP), Madrid, Spain
- Universitat Pompeu Fabra, Barcelona, Spain
- Corresponding Author. Address: ISGlobal, Institute for Global Health, C. Doctor Aiguader 88, 08003 Barcelona, Spain. E-mail: (M. Vrijheid)
| | - Xavier Basagaña
- ISGlobal, Barcelona, Spain
- Spanish Consortium for Research on Epidemiology and Public Health (CIBERESP), Madrid, Spain
- Universitat Pompeu Fabra, Barcelona, Spain
| | - Juan R. Gonzalez
- ISGlobal, Barcelona, Spain
- Spanish Consortium for Research on Epidemiology and Public Health (CIBERESP), Madrid, Spain
- Universitat Pompeu Fabra, Barcelona, Spain
| | - Vincent W. V. Jaddoe
- The Generation R Study Group, Erasmus University Medical Center, Rotterdam, The Netherlands
- Department of Pediatrics, Erasmus University Medical Center, Rotterdam, The Netherlands
| | - Genon Jensen
- Health & Environment Alliance (HEAL), Brussels, Belgium
| | - Hector C. Keun
- Department of Surgery & Cancer and Department of Metabolism, Digestion & Reproduction, Imperial College London, London, United Kingdom
| | - Rosemary R. C. McEachan
- Bradford Institute for Health Research, Bradford Teaching Hospitals NHS Foundation Trust, Bradford,United Kingdom
| | - Joana Porcel
- ISGlobal, Barcelona, Spain
- Spanish Consortium for Research on Epidemiology and Public Health (CIBERESP), Madrid, Spain
- Universitat Pompeu Fabra, Barcelona, Spain
| | - Valerie Siroux
- University Grenoble Alpes, Inserm, CNRS, IAB (Institute for Advanced Biosciences) Joint Research Center, Team of Environmental Epidemiology Applied to Development and Respiratory Health, Grenoble, France
| | - Morris A. Swertz
- University of Groningen, University Medical Center Groningen, Genomics Coordination Center, Groningen, The Netherlands
- University of Groningen, University Medical Center Groningen, Department of Genetics, Groningen, The Netherlands
| | - Cathrine Thomsen
- Department of Environmental Health, Norwegian Institute of Public Health, Oslo, Norway
| | - Gunn Marit Aasvang
- Department of Environmental Health, Norwegian Institute of Public Health, Oslo, Norway
| | - Sandra Andrušaitytė
- Department of Environmental Sciences, Vytautas Magnus University, Kaunas, Lithuania
| | - Karine Angeli
- French Agency for Food, Environmental and Occupational Health and Safety (ANSES), Risk Assessment Department, Maisons-Alfort, France
| | - Demetris Avraam
- Population Health Sciences Institute, Newcastle University, Newcastle, United Kingdom
| | - Ferran Ballester
- Spanish Consortium for Research on Epidemiology and Public Health (CIBERESP), Madrid, Spain
- Epidemiology and Environmental Health Joint Research Unit, FISABIO-Universitat Jaume I-Universitat de València, València, Spain
- Faculty of Nursing and Chiropody, Universitat de València, Valencia, Spain
| | - Paul Burton
- Population Health Sciences Institute, Newcastle University, Newcastle, United Kingdom
| | - Mariona Bustamante
- ISGlobal, Barcelona, Spain
- Spanish Consortium for Research on Epidemiology and Public Health (CIBERESP), Madrid, Spain
- Universitat Pompeu Fabra, Barcelona, Spain
| | - Maribel Casas
- ISGlobal, Barcelona, Spain
- Spanish Consortium for Research on Epidemiology and Public Health (CIBERESP), Madrid, Spain
- Universitat Pompeu Fabra, Barcelona, Spain
| | - Leda Chatzi
- Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California
| | - Cécile Chevrier
- University Rennes, Inserm, EHESP, Irset (Institut de recherche en santé, environnement et travail)—UMR_S 1085, Rennes, France
| | | | - David Conti
- Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California
| | - Amélie Crépet
- French Agency for Food, Environmental and Occupational Health and Safety (ANSES), Risk Assessment Department, Maisons-Alfort, France
| | - Payam Dadvand
- ISGlobal, Barcelona, Spain
- Spanish Consortium for Research on Epidemiology and Public Health (CIBERESP), Madrid, Spain
- Universitat Pompeu Fabra, Barcelona, Spain
| | - Liesbeth Duijts
- The Generation R Study Group, Erasmus University Medical Center, Rotterdam, The Netherlands
- Department of Pediatrics, Erasmus University Medical Center, Rotterdam, The Netherlands
| | - Esther van Enckevort
- University of Groningen, University Medical Center Groningen, Genomics Coordination Center, Groningen, The Netherlands
- University of Groningen, University Medical Center Groningen, Department of Genetics, Groningen, The Netherlands
| | - Ana Esplugues
- Spanish Consortium for Research on Epidemiology and Public Health (CIBERESP), Madrid, Spain
- Epidemiology and Environmental Health Joint Research Unit, FISABIO-Universitat Jaume I-Universitat de València, València, Spain
- Faculty of Nursing and Chiropody, Universitat de València, Valencia, Spain
| | - Serena Fossati
- ISGlobal, Barcelona, Spain
- Spanish Consortium for Research on Epidemiology and Public Health (CIBERESP), Madrid, Spain
- Universitat Pompeu Fabra, Barcelona, Spain
| | - Ronan Garlantezec
- CHU de Rennes, University Rennes, Inserm, EHESP, Irset (Institut de recherche en santé, environnement et travail)—UMR_S 1085, Rennes, France
| | - María Dolores Gómez Roig
- Institut de Recerca Sant Joan de Déu (IR-SJD), Barcelona, Spain
- Maternal and Child Health and Development Network II (SAMID II), Instituto de Salud Carlos III (ISCIII), Madrid, Spain
- BCNatal—Barcelona Center for Maternal Fetal and Neonatal Medicine, Hospital Sant Joan de Déu, Barcelona, Spain
| | | | - Kristine B. Gützkow
- Department of Environmental Health, Norwegian Institute of Public Health, Oslo, Norway
| | - Mònica Guxens
- ISGlobal, Barcelona, Spain
- Spanish Consortium for Research on Epidemiology and Public Health (CIBERESP), Madrid, Spain
- Universitat Pompeu Fabra, Barcelona, Spain
- Department of Child and Adolescence Psychiatry, Erasmus MC, University Medical Center, Rotterdam, The Netherlands
| | - Sido Haakma
- University of Groningen, University Medical Center Groningen, Genomics Coordination Center, Groningen, The Netherlands
- University of Groningen, University Medical Center Groningen, Department of Genetics, Groningen, The Netherlands
| | - Ellen V. S. Hessel
- National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands
| | - Lesley Hoyles
- Department of Biosciences, Nottingham Trent University, Nottingham, United Kingdom
| | - Eleanor Hyde
- University of Groningen, University Medical Center Groningen, Genomics Coordination Center, Groningen, The Netherlands
- University of Groningen, University Medical Center Groningen, Department of Genetics, Groningen, The Netherlands
| | - Jana Klanova
- RECETOX Centre, Faculty of Science, Masaryk University, Brno, Czech Republic
| | - Jacob D. van Klaveren
- National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands
| | - Andreas Kortenkamp
- Brunel University London, College of Health, Medicine and Life Sciences, Uxbridge, United Kingdom
| | - Laurent Le Brusquet
- University Paris-Saclay, CNRS, CentraleSupélec, Laboratoire des Signaux et Systèmes, Gif-sur-Yvette, France
| | - Ivonne Leenen
- Health & Environment Alliance (HEAL), Brussels, Belgium
| | - Aitana Lertxundi
- Spanish Consortium for Research on Epidemiology and Public Health (CIBERESP), Madrid, Spain
- University of Basque Country UPV/EHU, Basque Country, Bilbao, Spain
- Biodonostia, Research Health Institute, Donostia-San Sebastian, Spain
| | - Nerea Lertxundi
- University of Basque Country UPV/EHU, Basque Country, Bilbao, Spain
- Biodonostia, Research Health Institute, Donostia-San Sebastian, Spain
| | - Christos Lionis
- Department of Social Medicine, School of Medicine, University of Crete, Heraklion, Crete, Greece
| | - Sabrina Llop
- Spanish Consortium for Research on Epidemiology and Public Health (CIBERESP), Madrid, Spain
- Epidemiology and Environmental Health Joint Research Unit, FISABIO-Universitat Jaume I-Universitat de València, València, Spain
| | - Maria-Jose Lopez-Espinosa
- Spanish Consortium for Research on Epidemiology and Public Health (CIBERESP), Madrid, Spain
- Epidemiology and Environmental Health Joint Research Unit, FISABIO-Universitat Jaume I-Universitat de València, València, Spain
- Faculty of Nursing and Chiropody, Universitat de València, Valencia, Spain
| | - Sarah Lyon-Caen
- University Grenoble Alpes, Inserm, CNRS, IAB (Institute for Advanced Biosciences) Joint Research Center, Team of Environmental Epidemiology Applied to Development and Respiratory Health, Grenoble, France
| | - Lea Maitre
- ISGlobal, Barcelona, Spain
- Spanish Consortium for Research on Epidemiology and Public Health (CIBERESP), Madrid, Spain
- Universitat Pompeu Fabra, Barcelona, Spain
| | - Dan Mason
- Bradford Institute for Health Research, Bradford Teaching Hospitals NHS Foundation Trust, Bradford,United Kingdom
| | - Sandrine Mathy
- University Grenoble Alpes, CNRS, INRAE, Grenoble INP, GAEL, Grenoble, France
| | - Edurne Mazarico
- Institut de Recerca Sant Joan de Déu (IR-SJD), Barcelona, Spain
- Maternal and Child Health and Development Network II (SAMID II), Instituto de Salud Carlos III (ISCIII), Madrid, Spain
- BCNatal—Barcelona Center for Maternal Fetal and Neonatal Medicine, Hospital Sant Joan de Déu, Barcelona, Spain
| | - Tim Nawrot
- Centre for Environmental Sciences, Hasselt University, Hasselt, Belgium
- Centre for Health and Environment, Leuven University, Leuven, Belgium
| | - Mark Nieuwenhuijsen
- ISGlobal, Barcelona, Spain
- Spanish Consortium for Research on Epidemiology and Public Health (CIBERESP), Madrid, Spain
- Universitat Pompeu Fabra, Barcelona, Spain
| | - Rodney Ortiz
- ISGlobal, Barcelona, Spain
- Spanish Consortium for Research on Epidemiology and Public Health (CIBERESP), Madrid, Spain
- Universitat Pompeu Fabra, Barcelona, Spain
| | - Marie Pedersen
- Department of Public Health, University of Copenhagen, Copenhagen, Denmark
| | | | - Míriam Pérez-Cruz
- Institut de Recerca Sant Joan de Déu (IR-SJD), Barcelona, Spain
- Maternal and Child Health and Development Network II (SAMID II), Instituto de Salud Carlos III (ISCIII), Madrid, Spain
- BCNatal—Barcelona Center for Maternal Fetal and Neonatal Medicine, Hospital Sant Joan de Déu, Barcelona, Spain
| | - Claire Philippat
- University Grenoble Alpes, Inserm, CNRS, IAB (Institute for Advanced Biosciences) Joint Research Center, Team of Environmental Epidemiology Applied to Development and Respiratory Health, Grenoble, France
| | - Pavel Piler
- RECETOX Centre, Faculty of Science, Masaryk University, Brno, Czech Republic
| | - Costanza Pizzi
- Cancer Epidemiology Unit, Department of Medical Sciences, University of Turin, Turin, Italy
| | - Joane Quentin
- University Grenoble Alpes, Inserm, CNRS, IAB (Institute for Advanced Biosciences) Joint Research Center, Team of Environmental Epidemiology Applied to Development and Respiratory Health, Grenoble, France
| | - Lorenzo Richiardi
- Cancer Epidemiology Unit, Department of Medical Sciences, University of Turin, Turin, Italy
| | | | - Theano Roumeliotaki
- Department of Social Medicine, School of Medicine, University of Crete, Heraklion, Crete, Greece
| | | | | | - Susana Santos
- The Generation R Study Group, Erasmus University Medical Center, Rotterdam, The Netherlands
- Department of Pediatrics, Erasmus University Medical Center, Rotterdam, The Netherlands
| | - Alexandros P. Siskos
- Department of Surgery & Cancer and Department of Metabolism, Digestion & Reproduction, Imperial College London, London, United Kingdom
| | | | - Nikos Stratakis
- ISGlobal, Barcelona, Spain
- Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California
| | - Jordi Sunyer
- ISGlobal, Barcelona, Spain
- Spanish Consortium for Research on Epidemiology and Public Health (CIBERESP), Madrid, Spain
- Universitat Pompeu Fabra, Barcelona, Spain
| | - Arthur Tenenhaus
- University Paris-Saclay, CNRS, CentraleSupélec, Laboratoire des Signaux et Systèmes, Gif-sur-Yvette, France
| | - Marina Vafeiadi
- Department of Social Medicine, School of Medicine, University of Crete, Heraklion, Crete, Greece
| | - Rebecca C. Wilson
- Department of Public Health, Policy and Systems, University of Liverpool, Liverpool, United Kingdom
| | - John Wright
- Bradford Institute for Health Research, Bradford Teaching Hospitals NHS Foundation Trust, Bradford,United Kingdom
| | - Tiffany Yang
- Bradford Institute for Health Research, Bradford Teaching Hospitals NHS Foundation Trust, Bradford,United Kingdom
| | - Remy Slama
- University Grenoble Alpes, Inserm, CNRS, IAB (Institute for Advanced Biosciences) Joint Research Center, Team of Environmental Epidemiology Applied to Development and Respiratory Health, Grenoble, France
| |
Collapse
|
7
|
den Braver-Sewradj SP, van Benthem J, Staal YCM, Ezendam J, Piersma AH, Hessel EVS. Occupational exposure to hexavalent chromium. Part II. Hazard assessment of carcinogenic effects. Regul Toxicol Pharmacol 2021; 126:105045. [PMID: 34506880 DOI: 10.1016/j.yrtph.2021.105045] [Citation(s) in RCA: 19] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/01/2021] [Revised: 08/30/2021] [Accepted: 09/06/2021] [Indexed: 11/18/2022]
Abstract
Hexavalent chromium (Cr(VI)) compounds have been studied extensively and several agencies have described their toxicological profile. In the past, personnel of the Dutch Ministry of Defence may have been exposed to Cr(VI) during maintenance activities on NATO equipment. To investigate if this exposure may have caused irreversible adverse health effects, the Dutch National Institute for Public Health and the Environment (RIVM) summarized all available knowledge from previous evaluations. This information was complemented with a scoping review to retrieve new scientific literature. All scientific evidence was evaluated in workshops with external experts to come to an overview of irreversible adverse health effects that could be caused by occupational exposure to Cr(VI) compounds. This review provides the hazard assessment for occupational exposure to Cr(VI) and carcinogenic effects by integrating and weighting evidence provided by international agencies complemented with newly published studies. It was concluded that occupational exposure to Cr(VI) can cause lung cancer, nose and nasal sinus cancer in humans. Cr(VI) is suspected to cause stomach cancer and laryngeal cancer in humans. It is currently insufficiently clear if Cr(VI) can cause cancer of the small intestine, oral cavity, pancreas, prostate or bladder in humans.
Collapse
Affiliation(s)
| | - Jan van Benthem
- National Institute for Public Health and the Environment (RIVM), P.O. Box 1, 3720BA Bilthoven, the Netherlands
| | - Yvonne C M Staal
- National Institute for Public Health and the Environment (RIVM), P.O. Box 1, 3720BA Bilthoven, the Netherlands
| | - Janine Ezendam
- National Institute for Public Health and the Environment (RIVM), P.O. Box 1, 3720BA Bilthoven, the Netherlands
| | - Aldert H Piersma
- National Institute for Public Health and the Environment (RIVM), P.O. Box 1, 3720BA Bilthoven, the Netherlands
| | - Ellen V S Hessel
- National Institute for Public Health and the Environment (RIVM), P.O. Box 1, 3720BA Bilthoven, the Netherlands
| |
Collapse
|
8
|
de Leeuw VC, Pennings JLA, Hessel EVS, Piersma AH. Exploring the biological domain of the neural embryonic stem cell test (ESTn): Morphogenetic regulators, Hox genes and cell types, and their usefulness as biomarkers for embryotoxicity screening. Toxicology 2021; 454:152735. [PMID: 33636252 DOI: 10.1016/j.tox.2021.152735] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/27/2020] [Revised: 01/25/2021] [Accepted: 02/20/2021] [Indexed: 11/25/2022]
Abstract
Animal-free assessment of compound-induced developmental neurotoxicity will most likely be based on batteries of multiple in vitro tests. The optimal battery is built by combining tests with complementary biological domains that together ideally cover all relevant toxicity pathways. Thus, biological domain definition, i.e. which biological processes and cell types are represented, is an important assay characteristic for determining the place of assays in testing strategies. The murine neural embryonic stem cell test (ESTn) is employed to predict the developmental neurotoxicity of compounds. The aim of this study was to explore the biological domain of ESTn according to three groups of biomarker genes of early (neuro)development: morphogenetic regulators, Hox genes and cell type markers for the ectodermal and neural lineages. These biomarker groups were selected based on their crucial regulatory role in (neuro)development. Analysis of these genes in a series of previously generated whole transcriptome datasets of ESTn showed that at day 7 in culture cell differentiation resembled hindbrain/branchial/thoracic development between E6.5-E12.5 in vivo, with subsequent development into a mixed cell culture containing different neural subtypes, astrocytes and oligodendrocytes by day 13. In addition, the selected biomarkers showed common and distinct responses to compound exposure. Monitoring the biological domain of ESTn through gene expression patterns of morphogenetic regulators, Hox genes and cell type markers proved instrumental in providing mechanistic understanding of compound effects on neural differentiation in ESTn, and can aid in positioning of the test in a battery of complementary in vitro tests in integrated approaches to testing and assessment.
Collapse
Affiliation(s)
- Victoria C de Leeuw
- Centre for Health Protection, National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands; Institute for Risk Assessment Sciences (IRAS), Utrecht University, Utrecht, the Netherlands.
| | - Jeroen L A Pennings
- Centre for Health Protection, National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands
| | - Ellen V S Hessel
- Centre for Health Protection, National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands
| | - Aldert H Piersma
- Centre for Health Protection, National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands; Institute for Risk Assessment Sciences (IRAS), Utrecht University, Utrecht, the Netherlands
| |
Collapse
|
9
|
de Leeuw VC, van Oostrom CTM, Imholz S, Piersma AH, Hessel EVS, Dollé MET. Going Back and Forth: Episomal Vector Reprogramming of Peripheral Blood Mononuclear Cells to Induced Pluripotent Stem Cells and Subsequent Differentiation into Cardiomyocytes and Neuron-Astrocyte Co-cultures. Cell Reprogram 2020; 22:300-310. [PMID: 33146557 PMCID: PMC7757589 DOI: 10.1089/cell.2020.0040] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022] Open
Abstract
Human induced pluripotent stem cells (iPSCs) can capture the diversity in the general human population as well as provide deeper insight in cellular mechanisms. This makes them suitable to study both fundamental and applied research subjects, such as disease modeling, gene-environment interactions, personalized medicine, and chemical toxicity. In an independent laboratory, we were able to generate iPSCs originating from human peripheral blood mononuclear cells according to a modified version of a temporal episomal vector (EV)-based induction method. The iPSCs could subsequently be differentiated into two different lineages: mesoderm-derived cardiomyocytes and ectoderm-derived neuron-astrocyte co-cultures. It was shown that the neuron-astrocyte culture developed a mature phenotype within the course of five weeks and depending on the medium composition, network formation and neuron-astrocyte cell ratios could be modified. Although previously it has been described that iPSCs generated with this EV-based induction protocol could differentiate to mesenchymal stem cells, hepatocytes, cardiomyocytes, and basic neuronal cultures, we now demonstrate differentiation into a culture containing both neurons and astrocytes.
Collapse
Affiliation(s)
- Victoria C de Leeuw
- Centre for Health Protection, National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands.,Institute for Risk Assessment Sciences (IRAS), Utrecht University, Utrecht, The Netherlands
| | - Conny T M van Oostrom
- Centre for Health Protection, National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands
| | - Sandra Imholz
- Centre for Health Protection, National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands
| | - Aldert H Piersma
- Centre for Health Protection, National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands.,Institute for Risk Assessment Sciences (IRAS), Utrecht University, Utrecht, The Netherlands
| | - Ellen V S Hessel
- Centre for Health Protection, National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands
| | - Martijn E T Dollé
- Centre for Health Protection, National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands
| |
Collapse
|
10
|
Den Braver-Sewradj SP, Piersma A, Hessel EVS. An update on the hazard of and exposure to diethyl hexyl phthalate (DEHP) alternatives used in medical devices. Crit Rev Toxicol 2020; 50:650-672. [PMID: 33006299 DOI: 10.1080/10408444.2020.1816896] [Citation(s) in RCA: 26] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
Abstract
The use of the plasticizer diethyl hexyl phthalate (DEHP) in PVC medical devices is being questioned due to its potential reprotoxic effects in patients exposed as a result from migration from the device. This article reviews new information on migration and toxicity data of eleven alternative plasticizers that have previously been evaluated by the Danish EPA and the EU SCENIHR (Scientific Committee on Emerging and Newly Identified Health Risks). The new toxicity data did not justify the reconsideration of the critical NOAELs as established by SCENIHR and Danish EPA. The dataset on oral toxicity studies is rather complete for most substances; however, in particular for reproductive toxicity and endocrine disruption, data gaps still exist for many alternatives. Toxicity data on intravenous exposure are lacking and these are essential to conclude on hazard characteristics of alternatives that are poorly absorbed via the oral exposure route. Migration data are emerging for a few alternatives but still sparse for the majority of the alternatives. Taking all data on migration and toxicity in consideration, 1,2-cyclohexanedicarboxylic acid, diisononylester (DINCH), and tris(2-ethylhexyl)benzene-1,2,4-tricarboxylate display a more favorable profile compared to DEHP. For these promising alternatives, a risk assessment for use in medical devices should be conducted. As a next step, we recommend the (further) generation of relevant migration data and, where needed, relevant toxicity data for the alternative substances, in order to be able to conduct a benefit-risk analysis of DEHP and the alternatives as obligatory in the new European Union Medical Device Regulation.
Collapse
Affiliation(s)
| | - Aldert Piersma
- National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands.,Institute for Risk Assessment Sciences (IRAS), Utrecht University, Utrecht, The Netherlands
| | - Ellen V S Hessel
- National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands
| |
Collapse
|
11
|
den Braver-Sewradj SP, van Spronsen R, Hessel EVS. Substitution of bisphenol A: a review of the carcinogenicity, reproductive toxicity, and endocrine disruption potential of alternative substances. Crit Rev Toxicol 2020; 50:128-147. [DOI: 10.1080/10408444.2019.1701986] [Citation(s) in RCA: 49] [Impact Index Per Article: 12.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
Affiliation(s)
| | - Rob van Spronsen
- National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands
| | - Ellen V. S. Hessel
- National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands
| |
Collapse
|
12
|
de Leeuw VC, Hessel EVS, Piersma AH. Look-alikes may not act alike: Gene expression regulation and cell-type-specific responses of three valproic acid analogues in the neural embryonic stem cell test (ESTn). Toxicol Lett 2018; 303:28-37. [PMID: 30578912 DOI: 10.1016/j.toxlet.2018.12.005] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/22/2018] [Revised: 12/07/2018] [Accepted: 12/13/2018] [Indexed: 12/20/2022]
Abstract
In vitro assays to assess developmental neurotoxicity of chemicals are highly desirable. The murine neural embryonic stem cell test (ESTn) can mimic parts of early differentiation of embryonic brain and may therefore be useful for this purpose. The aim of this study was to investigate whether this test is able to rank the toxic potencies of three valproic acid analogues and to study their mode of action by investigating their individual effects on four cell types: stem cells, neurons, astrocytes and neural crest cells. Using immunocytochemical read-outs and qPCR for cell type-specific genes, the effects of valproic acid (VPA), 2-ethylhexanoic acid (EHA) and 2-ethyl-4-methylpentanoic (EMPA) were assessed. VPA and EHA but not EMPA downregulated cell type-specific differentiation makers and upregulated stem cell related markers (Fut4, Cdh1) at different time points during differentiation. Expression of Gfap, a marker for astrocytes, was dramatically downregulated by VPA and EHA, but not by EMPA. This finding was verified using immunostainings. Based on the number and extent of genes regulated by the three compounds, relative potencies were determined as VPA > EHA > EMPA, which is consistent with in vivo developmental toxicity potency ranking of these compounds. Thus, ESTn using a combination of morphology, gene and protein expression readouts, may provide a medium-throughput system for monitoring the effects of compounds on differentiation of cell types in early brain development.
Collapse
Affiliation(s)
- Victoria C de Leeuw
- Center for Health Protection, National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands; Institute for Risk Assessment Sciences (IRAS), Utrecht University, Utrecht, the Netherlands.
| | - Ellen V S Hessel
- Center for Health Protection, National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands
| | - Aldert H Piersma
- Center for Health Protection, National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands; Institute for Risk Assessment Sciences (IRAS), Utrecht University, Utrecht, the Netherlands
| |
Collapse
|
13
|
Hessel EVS, Staal YCM, Piersma AH. Design and validation of an ontology-driven animal-free testing strategy for developmental neurotoxicity testing. Toxicol Appl Pharmacol 2018; 354:136-152. [PMID: 29544899 DOI: 10.1016/j.taap.2018.03.013] [Citation(s) in RCA: 21] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/08/2017] [Revised: 02/26/2018] [Accepted: 03/11/2018] [Indexed: 12/26/2022]
Abstract
Developmental neurotoxicity entails one of the most complex areas in toxicology. Animal studies provide only limited information as to human relevance. A multitude of alternative models have been developed over the years, providing insights into mechanisms of action. We give an overview of fundamental processes in neural tube formation, brain development and neural specification, aiming at illustrating complexity rather than comprehensiveness. We also give a flavor of the wealth of alternative methods in this area. Given the impressive progress in mechanistic knowledge of human biology and toxicology, the time is right for a conceptual approach for designing testing strategies that cover the integral mechanistic landscape of developmental neurotoxicity. The ontology approach provides a framework for defining this landscape, upon which an integral in silico model for predicting toxicity can be built. It subsequently directs the selection of in vitro assays for rate-limiting events in the biological network, to feed parameter tuning in the model, leading to prediction of the toxicological outcome. Validation of such models requires primary attention to coverage of the biological domain, rather than classical predictive value of individual tests. Proofs of concept for such an approach are already available. The challenge is in mining modern biology, toxicology and chemical information to feed intelligent designs, which will define testing strategies for neurodevelopmental toxicity testing.
Collapse
Affiliation(s)
- Ellen V S Hessel
- Center for Health Protection, National Institute for Public Health and The Environment (RIVM), P.O. Box 1, 3720BA Bilthoven, The Netherlands.
| | - Yvonne C M Staal
- Center for Health Protection, National Institute for Public Health and The Environment (RIVM), P.O. Box 1, 3720BA Bilthoven, The Netherlands
| | - Aldert H Piersma
- Center for Health Protection, National Institute for Public Health and The Environment (RIVM), P.O. Box 1, 3720BA Bilthoven, The Netherlands; Institute for Risk Assessment Sciences (IRAS), Utrecht University, Utrecht, The Netherlands
| |
Collapse
|
14
|
Fritsche E, Grandjean P, Crofton KM, Aschner M, Goldberg A, Heinonen T, Hessel EVS, Hogberg HT, Bennekou SH, Lein PJ, Leist M, Mundy WR, Paparella M, Piersma AH, Sachana M, Schmuck G, Solecki R, Terron A, Monnet-Tschudi F, Wilks MF, Witters H, Zurich MG, Bal-Price A. Consensus statement on the need for innovation, transition and implementation of developmental neurotoxicity (DNT) testing for regulatory purposes. Toxicol Appl Pharmacol 2018; 354:3-6. [PMID: 29447839 PMCID: PMC6097873 DOI: 10.1016/j.taap.2018.02.004] [Citation(s) in RCA: 81] [Impact Index Per Article: 13.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/02/2018] [Revised: 02/09/2018] [Accepted: 02/10/2018] [Indexed: 01/15/2023]
Abstract
This consensus statement voices the agreement of scientific stakeholders from regulatory agencies, academia and industry that a new framework needs adopting for assessment of chemicals with the potential to disrupt brain development. An increased prevalence of neurodevelopmental disorders in children has been observed that cannot solely be explained by genetics and recently pre- and postnatal exposure to environmental chemicals has been suspected as a causal factor. There is only very limited information on neurodevelopmental toxicity, leaving thousands of chemicals, that are present in the environment, with high uncertainty concerning their developmental neurotoxicity (DNT) potential. Closing this data gap with the current test guideline approach is not feasible, because the in vivo bioassays are far too resource-intensive concerning time, money and number of animals. A variety of in vitro methods are now available, that have the potential to close this data gap by permitting mode-of-action-based DNT testing employing human stem cells-derived neuronal/glial models. In vitro DNT data together with in silico approaches will in the future allow development of predictive models for DNT effects. The ultimate application goals of these new approach methods for DNT testing are their usage for different regulatory purposes. An increased prevalence of neurodevelopmental disorders in children is observed. There is very limited information on neurodevelopmental toxicity (DNT) induced by environmental chemicals. A new framework is required for assessment of chemicals with the potential to disrupt brain development. In vitro DNT data together with in silico approaches should be used for regulatory purposes.
Collapse
Affiliation(s)
- Ellen Fritsche
- IUF - Leibniz Research Institute for Environmental Medicine, Duesseldorf, Germany
| | - Philippe Grandjean
- University of Southern Denmark, Harvard T.H. Chan School of Public Health, USA
| | | | | | - Alan Goldberg
- Bloomberg School of Public Health, Founding Director (Emeritus) of Center for Alternatives to Animal Testing (CAAT), Johns Hopkins University, Baltimore, USA; Global Food Ethics, Johns Hopkins University, Baltimore, USA
| | - Tuula Heinonen
- Finnish Centre for Alternative Methods (FICAM), University of Tampere, Tampere, Finland
| | - Ellen V S Hessel
- National Institute for Public Health and the Environment, RIVM Center for Health Protection, Bilthoven, Netherlands
| | - Helena T Hogberg
- Centre for Alternatives to Animal Testing (CAAT), Johns Hopkins University, Baltimore, USA
| | | | - Pamela J Lein
- Department of Molecular Biosciences, School of Veterinary Medicine, University of California Davis, Davis, USA
| | - Marcel Leist
- CAAT - Centre for Alternatives to Animal Testing, University of Konstanz, Konstanz, Germany
| | | | | | - Aldert H Piersma
- RIVM Center for Health Protection, Bilthoven and Institute for Risk Assessment Sciences, Utrecht University, Utrecht, Netherlands
| | - Magdalini Sachana
- Organisation for Economic Co-operation and Development (OECD), Paris, France
| | | | - Roland Solecki
- Federal Institute for Risk Assessment (BfR), Berlin, Germany
| | | | | | - Martin F Wilks
- SCAHT - Swiss Centre for Applied Human Toxicology, University of Basel, Basel, Switzerland
| | - Hilda Witters
- VITO, Flemish Institute for Technological Research, Unit Environmental Risk and Health, Belgium
| | | | - Anna Bal-Price
- European Commission -DG Joint Research Centre (JRC), Ispra, Italy.
| |
Collapse
|
15
|
van Campen JS, Hessel EVS, Bohmbach K, Rizzi G, Lucassen PJ, Lakshmi Turimella S, Umeoka EHL, Meerhoff GF, Braun KPJ, de Graan PNE, Joëls M. Stress and Corticosteroids Aggravate Morphological Changes in the Dentate Gyrus after Early-Life Experimental Febrile Seizures in Mice. Front Endocrinol (Lausanne) 2018; 9:3. [PMID: 29434572 PMCID: PMC5790804 DOI: 10.3389/fendo.2018.00003] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/19/2017] [Accepted: 01/05/2018] [Indexed: 12/17/2022] Open
Abstract
Stress is the most frequently self-reported seizure precipitant in patients with epilepsy. Moreover, a relation between ear stress and epilepsy has been suggested. Although ear stress and stress hormones are known to influence seizure threshold in rodents, effects on the development of epilepsy (epileptogenesis) are still unclear. Therefore, we studied the consequences of ear corticosteroid exposure for epileptogenesis, under highly controlled conditions in an animal model. Experimental febrile seizures (eFS) were elicited in 10-day-old mice by warm-air induced hyperthermia, while a control group was exposed to a normothermic condition. In the following 2 weeks, mice received either seven corticosterone or vehicle injections or were left undisturbed. Specific measures indicative for epileptogenesis were examined at 25 days of age and compared with vehicle injected or untreated mice. We examined structural [neurogenesis, dendritic morphology, and mossy fiber sprouting (MFS)] and functional (glutamatergic postsynaptic currents and long-term potentiation) plasticity in the dentate gyrus (DG). We found that differences in DG morphology induced by eFS were aggravated by repetitive (mildly stressful) vehicle injections and corticosterone exposure. In the injected groups, eFS were associated with decreases in neurogenesis, and increases in cell proliferation, dendritic length, and spine density. No group differences were found in MFS. Despite these changes in DG morphology, no effects of eFS were found on functional plasticity. We conclude that corticosterone exposure during early epileptogenesis elicited by eFS aggravates morphological, but not functional, changes in the DG, which partly supports the hypothesis that ear stress stimulates epileptogenesis.
Collapse
Affiliation(s)
- Jolien S. van Campen
- Department of Translational Neuroscience, Brain Center Rudolf Magnus, University Medical Center Utrecht, Utrecht, Netherlands
- Department of Child Neurology, Brain Center Rudolf Magnus, University Medical Center Utrecht, Utrecht, Netherlands
| | - Ellen V. S. Hessel
- Department of Translational Neuroscience, Brain Center Rudolf Magnus, University Medical Center Utrecht, Utrecht, Netherlands
| | - Kirsten Bohmbach
- Department of Translational Neuroscience, Brain Center Rudolf Magnus, University Medical Center Utrecht, Utrecht, Netherlands
| | - Giorgio Rizzi
- Department of Translational Neuroscience, Brain Center Rudolf Magnus, University Medical Center Utrecht, Utrecht, Netherlands
| | - Paul J. Lucassen
- Swammerdam Institute for Life Sciences, Center for Neuroscience, University of Amsterdam, Amsterdam, Netherlands
| | - Sada Lakshmi Turimella
- Department of Translational Neuroscience, Brain Center Rudolf Magnus, University Medical Center Utrecht, Utrecht, Netherlands
| | - Eduardo H. L. Umeoka
- Department of Translational Neuroscience, Brain Center Rudolf Magnus, University Medical Center Utrecht, Utrecht, Netherlands
- Neursocience and Behavioral Sciences Department, Ribeirão Preto School of Medicine, University of São Paulo, Ribeirão Preto, Brazil
| | - Gideon F. Meerhoff
- Swammerdam Institute for Life Sciences, Center for Neuroscience, University of Amsterdam, Amsterdam, Netherlands
| | - Kees P. J. Braun
- Department of Child Neurology, Brain Center Rudolf Magnus, University Medical Center Utrecht, Utrecht, Netherlands
| | - Pierre N. E. de Graan
- Department of Translational Neuroscience, Brain Center Rudolf Magnus, University Medical Center Utrecht, Utrecht, Netherlands
| | - Marian Joëls
- Department of Translational Neuroscience, Brain Center Rudolf Magnus, University Medical Center Utrecht, Utrecht, Netherlands
| |
Collapse
|
16
|
Hessel EVS, van Lith HA, Wolterink-Donselaar IG, de Wit M, Groot Koerkamp MJA, Holstege FCP, Kas MJH, Fernandes C, de Graan PNE. Mapping of aFEB3homologous febrile seizure locus on mouse chromosome 2 containing candidate genesScn1aandScn3a. Eur J Neurosci 2016; 44:2950-2957. [DOI: 10.1111/ejn.13420] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/16/2016] [Revised: 07/10/2016] [Accepted: 08/09/2016] [Indexed: 01/05/2023]
Affiliation(s)
- Ellen V. S. Hessel
- Brain Center Rudolf Magnus; Department of Translational Neuroscience; University Medical Center Utrecht; Universiteitsweg 100 3584 CG Utrecht The Netherlands
| | - Hein A. van Lith
- Division of Animal Welfare & Laboratory Animal Science; Department of Animals in Science & Society; Faculty of Veterinary Medicine and Brain Center Rudolf Magnus; Utrecht University; Utrecht The Netherlands
| | - Inge G. Wolterink-Donselaar
- Brain Center Rudolf Magnus; Department of Translational Neuroscience; University Medical Center Utrecht; Universiteitsweg 100 3584 CG Utrecht The Netherlands
| | - Marina de Wit
- Brain Center Rudolf Magnus; Department of Translational Neuroscience; University Medical Center Utrecht; Universiteitsweg 100 3584 CG Utrecht The Netherlands
| | | | - Frank C. P. Holstege
- Department of Molecular Cancer Research; University Medical Center Utrecht; Utrecht The Netherlands
| | - Martien J. H. Kas
- Brain Center Rudolf Magnus; Department of Translational Neuroscience; University Medical Center Utrecht; Universiteitsweg 100 3584 CG Utrecht The Netherlands
- Groningen Institute for Evolutionary Life Sciences; University of Groningen; Groningen The Netherlands
| | - Cathy Fernandes
- Social, Genetic & Developmental Psychiatry Centre; Institute of Psychiatry; Psychology and Neuroscience; King's College London; London UK
| | - Pierre N. E. de Graan
- Brain Center Rudolf Magnus; Department of Translational Neuroscience; University Medical Center Utrecht; Universiteitsweg 100 3584 CG Utrecht The Netherlands
| |
Collapse
|
17
|
Hessel EVS, Ezendam J, van Broekhuizen FA, Hakkert B, DeWitt J, Granum B, Guzylack L, Lawrence BP, Penninks A, Rooney AA, Piersma AH, van Loveren H. Assessment of recent developmental immunotoxicity studies with bisphenol A in the context of the 2015 EFSA t-TDI. Reprod Toxicol 2016; 65:448-456. [PMID: 27352639 DOI: 10.1016/j.reprotox.2016.06.020] [Citation(s) in RCA: 26] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/03/2016] [Revised: 06/21/2016] [Accepted: 06/24/2016] [Indexed: 10/21/2022]
Abstract
Humans are exposed to bisphenol A (BPA) mainly through the diet, air, dust, skin contact and water. There are concerns about adverse health effects in humans due to exposure to bisphenol A (BPA). The European Food Safety Authority (EFSA) has extensively reviewed the available literature to establish a temporary Tolerable Daily Intake (t-TDI). This exposure level was based on all available literature published before the end of 2012. Since then, new experimental animal studies have emerged, including those that identified effects of BPA on the immune system after developmental exposure. These studies indicate that developmental immunotoxicity might occur at lower dose levels than previously observed and on which the current EFSA t-TDI is based. The Dutch National Institute for Public Health and the Environment (RIVM) organized an expert workshop in September 2015 to consider recently published studies on the developmental immunotoxicity of bisphenol A (BPA). Key studies were discussed in the context of other experimental studies. The workshop concluded that these new experimental studies provide credible evidence for adverse immune effects after developmental exposure to BPA at 5μg/kg BW/day from gestation day 15 to postnatal day 21. Supportive evidence for adverse immune effects in similar dose ranges was obtained from other publications that were discussed during the workshop. The dose level associated with adverse immune effects is considerably lower than the dose used by EFSA for deriving the t-TDI. The workshop unanimously concluded that the current EFSA t-TDI warrants reconsideration in the context of all currently available data.
Collapse
Affiliation(s)
- Ellen V S Hessel
- Center for Health Protection, National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands
| | - Janine Ezendam
- Center for Health Protection, National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands
| | - Fleur A van Broekhuizen
- Center for Safety of Substances and Products, National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands
| | - Betty Hakkert
- Center for Safety of Substances and Products, National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands
| | - Jamie DeWitt
- Department of Pharmacology and Toxicology, East Carolina University, Greenville, NC, USA
| | - Berit Granum
- Department of Toxicology and Risk Assessment, Norwegian Institute of Public Health (NIPH), Oslo, Norway
| | - Laurence Guzylack
- Department of Intestinal Development, Xenobiotics, and Immunotoxicology, Institut National de la Recherche Agronomique (INRA), Research Centre in Food Toxicology (Toxalim), Université de Toulouse, INRA, Toulouse, France
| | - B Paige Lawrence
- Department of Environmental Medicine and Department of Microbiology and Immunology, University of Rochester School of Medicine & Dentistry, Rochester, NY, USA
| | - Andre Penninks
- Formerly Department of Toxicology and Risk Assessment, TNO Triskelion BV, Zeist, The Netherlands
| | - Andrew A Rooney
- National Toxicology Program, Office of Health Assessment and Translation, National Institute of Environmental Health Sciences, Research Triangle Park, NC, USA
| | - Aldert H Piersma
- Center for Health Protection, National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands; Institute for Risk Assessment Sciences, Veterinary Faculty, University of Utrecht, Utrecht, The Netherlands.
| | - Henk van Loveren
- Center for Health Protection, National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands; Currently Department of Toxicogenomics, Maastricht University, Maastricht, The Netherlands
| |
Collapse
|
18
|
van der Hel WS, Hessel EVS, Bos IWM, Mulder SD, Verlinde SAMW, van Eijsden P, de Graan PNE. Persistent reduction of hippocampal glutamine synthetase expression after status epilepticus in immature rats. Eur J Neurosci 2014; 40:3711-9. [PMID: 25350774 DOI: 10.1111/ejn.12756] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/17/2013] [Revised: 09/13/2014] [Accepted: 09/22/2014] [Indexed: 01/16/2023]
Abstract
Mesiotemporal sclerosis (MTS), the most frequent form of drug-resistant temporal lobe epilepsy, often develops after an initial precipitating injury affecting the immature brain. To analyse early processes in epileptogenesis we used the juvenile pilocarpine model to study status epilepticus (SE)-induced changes in expression of key components in the glutamate-glutamine cycle, known to be affected in MTS patients. SE was induced by Li(+) /pilocarpine injection in 21-day-old rats. At 2-19 weeks after SE hippocampal protein expression was analysed by immunohistochemistry and neuron damage by FluoroJade staining. Spontaneous seizures occurred in at least 44% of animals 15-18 weeks after SE. As expected in this model, we did not observe loss of principal hippocampal neurons. Neuron damage was most pronounced in the hilus, where we also detected progressive loss of parvalbumin-positive GABAergic interneurons. Hilar neuron loss (or end-folium sclerosis), a common feature in patients with MTS, was accompanied by a progressively decreased glutamine synthetase (GS)-immunoreactivity from 2 (-15%) to 19 weeks (-33.5%) after SE. Immunoreactivity for excitatory amino-acid transporters, vesicular glutamate transporter 1 and glial fibrillary acidic protein was unaffected. Our data show that SE elicited in 21-day-old rats induces a progressive reduction in hilar GS expression without affecting other key components of the glutamate-glutamine cycle. Reduced expression of glial enzyme GS was first detected 2 weeks after SE, and thus clearly before spontaneous recurrent seizures occurred. These results support the hypothesis that reduced GS expression is an early event in the development of hippocampal sclerosis in MTS patients and emphasize the importance of astrocytes in early epileptogenesis.
Collapse
Affiliation(s)
- W Saskia van der Hel
- Department of Translational Neuroscience, Brain Center Rudolf Magnus, University Medical Center Utrecht, Universiteitsweg 100, 3584CG, Utrecht, The Netherlands; Division of Surgical Specialties, Department of Anatomy, University Medical Center Utrecht, Utrecht, The Netherlands
| | | | | | | | | | | | | |
Collapse
|
19
|
Hessel EVS, de Wit M, Wolterink-Donselaar IG, Karst H, de Graaff E, van Lith HA, de Bruijn E, de Sonnaville S, Verbeek NE, Lindhout D, de Kovel CGF, Koeleman BPC, van Kempen M, Brilstra E, Cuppen E, Loos M, Spijker SS, Kan AA, Baars SE, van Rijen PC, Gosselaar PH, Groot Koerkamp MJA, Holstege FCP, van Duijn C, Vergeer J, Moll HA, Taubøll E, Heuser K, Ramakers GMJ, Pasterkamp RJ, van Nieuwenhuizen O, Hoogenraad CC, Kas MJH, de Graan PNE. Identification of Srp9 as a febrile seizure susceptibility gene. Ann Clin Transl Neurol 2014; 1:239-50. [PMID: 25590037 PMCID: PMC4292741 DOI: 10.1002/acn3.48] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/04/2014] [Accepted: 02/07/2014] [Indexed: 12/16/2022] Open
Abstract
OBJECTIVE Febrile seizures (FS) are the most common seizure type in young children. Complex FS are a risk factor for mesial temporal lobe epilepsy (mTLE). To identify new FS susceptibility genes we used a forward genetic strategy in mice and subsequently analyzed candidate genes in humans. METHODS We mapped a quantitative trait locus (QTL1) for hyperthermia-induced FS on mouse chromosome 1, containing the signal recognition particle 9 (Srp9) gene. Effects of differential Srp9 expression were assessed in vivo and in vitro. Hippocampal SRP9 expression and genetic association were analyzed in FS and mTLE patients. RESULTS Srp9 was differentially expressed between parental strains C57BL/6J and A/J. Chromosome substitution strain 1 (CSS1) mice exhibited lower FS susceptibility and Srp9 expression than C57BL/6J mice. In vivo knockdown of brain Srp9 reduced FS susceptibility. Mice with reduced Srp9 expression and FS susceptibility, exhibited reduced hippocampal AMPA and NMDA currents. Downregulation of neuronal Srp9 reduced surface expression of AMPA receptor subunit GluA1. mTLE patients with antecedent FS had higher SRP9 expression than patients without. SRP9 promoter SNP rs12403575(G/A) was genetically associated with FS and mTLE. INTERPRETATION Our findings identify SRP9 as a novel FS susceptibility gene and indicate that SRP9 conveys its effects through endoplasmic reticulum (ER)-dependent synthesis and trafficking of membrane proteins, such as glutamate receptors. Discovery of this new FS gene and mechanism may provide new leads for early diagnosis and treatment of children with complex FS at risk for mTLE.
Collapse
Affiliation(s)
- Ellen V S Hessel
- Department of Translational Neuroscience, Brain Center Rudolf Magnus, University Medical Center UtrechtUtrecht, The Netherlands
| | - Marina de Wit
- Department of Translational Neuroscience, Brain Center Rudolf Magnus, University Medical Center UtrechtUtrecht, The Netherlands
| | - Inge G Wolterink-Donselaar
- Department of Translational Neuroscience, Brain Center Rudolf Magnus, University Medical Center UtrechtUtrecht, The Netherlands
| | - Henk Karst
- Department of Translational Neuroscience, Brain Center Rudolf Magnus, University Medical Center UtrechtUtrecht, The Netherlands
| | - Esther de Graaff
- Cell Biology, Faculty of Science, Utrecht UniversityUtrecht, The Netherlands
| | - Hein A van Lith
- Program Emotion and Cognition, Division of Animal Welfare and Laboratory Animal Science, Department of Animals in Science and Society, Faculty of Veterinary Medicine, Utrecht University and Brain Center Rudolf Magnus, University Medical Center UtrechtUtrecht, The Netherlands
| | - Ewart de Bruijn
- Hubrecht Institute-KNAW and University Medical Center UtrechtUtrecht, The Netherlands
| | - Sophietje de Sonnaville
- Department of Translational Neuroscience, Brain Center Rudolf Magnus, University Medical Center UtrechtUtrecht, The Netherlands
| | - Nienke E Verbeek
- Department of Medical Genetics, University Medical Center UtrechtUtrecht, The Netherlands
| | - Dick Lindhout
- Department of Medical Genetics, University Medical Center UtrechtUtrecht, The Netherlands
- SEIN Epilepsy Institute in the NetherlandsHeemstede, The Netherlands
| | - Carolien G F de Kovel
- Department of Medical Genetics, University Medical Center UtrechtUtrecht, The Netherlands
| | - Bobby P C Koeleman
- Department of Medical Genetics, University Medical Center UtrechtUtrecht, The Netherlands
| | - Marjan van Kempen
- Department of Medical Genetics, University Medical Center UtrechtUtrecht, The Netherlands
| | - Eva Brilstra
- Department of Medical Genetics, University Medical Center UtrechtUtrecht, The Netherlands
| | - Edwin Cuppen
- Hubrecht Institute-KNAW and University Medical Center UtrechtUtrecht, The Netherlands
- Department of Medical Genetics, University Medical Center UtrechtUtrecht, The Netherlands
| | - Maarten Loos
- Department of Molecular and Cellular Neurobiology, Center for Neurogenomics and Cognitive Research, Neuroscience Campus Amsterdam, VU UniversityAmsterdam, The Netherlands
| | - Sabine S Spijker
- Department of Molecular and Cellular Neurobiology, Center for Neurogenomics and Cognitive Research, Neuroscience Campus Amsterdam, VU UniversityAmsterdam, The Netherlands
| | - Anne A Kan
- Department of Translational Neuroscience, Brain Center Rudolf Magnus, University Medical Center UtrechtUtrecht, The Netherlands
| | - Susanne E Baars
- Department of Translational Neuroscience, Brain Center Rudolf Magnus, University Medical Center UtrechtUtrecht, The Netherlands
- Master program Neuroscience and Cognition, Utrecht UniversityUtrecht, The Netherlands
| | - Peter C van Rijen
- Department of Neurosurgery, Brain Center Rudolf Magnus, University Medical Center UtrechtUtrecht, The Netherlands
| | - Peter H Gosselaar
- Department of Neurosurgery, Brain Center Rudolf Magnus, University Medical Center UtrechtUtrecht, The Netherlands
| | | | - Frank C P Holstege
- Department of Molecular Cancer Research, University Medical Center UtrechtUtrecht, The Netherlands
| | - Cornelia van Duijn
- Department of Epidemiology, Erasmus University Medical CenterRotterdam, The Netherlands
| | - Jeanette Vergeer
- Department of Epidemiology, Erasmus University Medical CenterRotterdam, The Netherlands
| | - Henriette A Moll
- Department of Pediatrics, Erasmus Medical CenterRotterdam, The Netherlands
| | - Erik Taubøll
- Department of Neurology, Oslo University HospitalOslo, Norway
| | - Kjell Heuser
- Department of Neurology, Oslo University HospitalOslo, Norway
| | - Geert M J Ramakers
- Department of Translational Neuroscience, Brain Center Rudolf Magnus, University Medical Center UtrechtUtrecht, The Netherlands
| | - R Jeroen Pasterkamp
- Department of Translational Neuroscience, Brain Center Rudolf Magnus, University Medical Center UtrechtUtrecht, The Netherlands
| | - Onno van Nieuwenhuizen
- Department of Child Neurology, Brain Center Rudolf Magnus, University Medical Center UtrechtUtrecht, The Netherlands
| | - Casper C Hoogenraad
- Cell Biology, Faculty of Science, Utrecht UniversityUtrecht, The Netherlands
| | - Martien J H Kas
- Department of Translational Neuroscience, Brain Center Rudolf Magnus, University Medical Center UtrechtUtrecht, The Netherlands
| | - Pierre N E de Graan
- Department of Translational Neuroscience, Brain Center Rudolf Magnus, University Medical Center UtrechtUtrecht, The Netherlands
| |
Collapse
|
20
|
Noorlander CW, Tijsseling D, Hessel EVS, de Vries WB, Derks JB, Visser GHA, de Graan PNE. Antenatal glucocorticoid treatment affects hippocampal development in mice. PLoS One 2014; 9:e85671. [PMID: 24465645 PMCID: PMC3899077 DOI: 10.1371/journal.pone.0085671] [Citation(s) in RCA: 49] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/02/2013] [Accepted: 11/29/2013] [Indexed: 11/18/2022] Open
Abstract
Synthetic glucocorticoids are administered to pregnant women at risk for preterm delivery, to enhance fetal lung maturation. The benefit of this treatment is well established, however caution is necessary because of possible unwanted side effects on development of different organ systems, including the brain. Actions of glucocorticoids are mediated by corticosteroid receptors, which are highly expressed in the hippocampus, a brain structure involved in cognitive functions. Therefore, we analyzed the effects of a single antenatal dexamethasone treatment on the development of the mouse hippocampus. A clinically relevant dose of dexamethasone (0.4 mg/kg) was administered to pregnant mice at embryonic day 15.5 and the hippocampus was analyzed from embryonic day 16 until adulthood. We investigated the effects of dexamethasone treatment on anatomical changes, apoptosis and proliferation in the hippocampus, hippocampal volume and on total body weight. Our results show that dexamethasone treatment reduced body weight and hippocampal volume transiently during development, but these effects were no longer detected at adulthood. Dexamethasone treatment increased the number of apoptotic cells in the hippocampus until birth, but postnatally no effects of dexamethasone treatment on apoptosis were found. During the phase with increased apoptosis, dexamethasone treatment reduced the number of proliferating cells in the subgranular zone of the dentate gyrus. The number of proliferative cells was increased at postnatal day 5 and 10, but was decreased again at the adult stage. This latter long-term and negative effect of antenatal dexamethasone treatment on the number of proliferative cells in the hippocampus may have important implications for hippocampal network function.
Collapse
Affiliation(s)
- Cornelle W. Noorlander
- Brain Center Rudolf Magnus, Department of Neuroscience and Pharmacology, University Medical Center Utrecht, Utrecht, The Netherlands
- Department of Obstetrics, University Medical Center Utrecht, Utrecht, The Netherlands
| | - Deodata Tijsseling
- Department of Obstetrics, University Medical Center Utrecht, Utrecht, The Netherlands
- * E-mail:
| | - Ellen V. S. Hessel
- Brain Center Rudolf Magnus, Department of Neuroscience and Pharmacology, University Medical Center Utrecht, Utrecht, The Netherlands
| | - Willem B. de Vries
- Department of Neonatology, University Medical Center Utrecht, Utrecht, The Netherlands
| | - Jan B. Derks
- Department of Obstetrics, University Medical Center Utrecht, Utrecht, The Netherlands
| | - Gerard H. A. Visser
- Department of Obstetrics, University Medical Center Utrecht, Utrecht, The Netherlands
| | - Pierre N. E. de Graan
- Brain Center Rudolf Magnus, Department of Neuroscience and Pharmacology, University Medical Center Utrecht, Utrecht, The Netherlands
| |
Collapse
|
21
|
Kasperavičiūtė D, Catarino CB, Matarin M, Leu C, Novy J, Tostevin A, Leal B, Hessel EVS, Hallmann K, Hildebrand MS, Dahl HHM, Ryten M, Trabzuni D, Ramasamy A, Alhusaini S, Doherty CP, Dorn T, Hansen J, Krämer G, Steinhoff BJ, Zumsteg D, Duncan S, Kälviäinen RK, Eriksson KJ, Kantanen AM, Pandolfo M, Gruber-Sedlmayr U, Schlachter K, Reinthaler EM, Stogmann E, Zimprich F, Théâtre E, Smith C, O’Brien TJ, Meng Tan K, Petrovski S, Robbiano A, Paravidino R, Zara F, Striano P, Sperling MR, Buono RJ, Hakonarson H, Chaves J, Costa PP, Silva BM, da Silva AM, de Graan PNE, Koeleman BPC, Becker A, Schoch S, von Lehe M, Reif PS, Rosenow F, Becker F, Weber Y, Lerche H, Rössler K, Buchfelder M, Hamer HM, Kobow K, Coras R, Blumcke I, Scheffer IE, Berkovic SF, Weale ME, Delanty N, Depondt C, Cavalleri GL, Kunz WS, Sisodiya SM. Epilepsy, hippocampal sclerosis and febrile seizures linked by common genetic variation around SCN1A. Brain 2013; 136:3140-50. [PMID: 24014518 PMCID: PMC3784283 DOI: 10.1093/brain/awt233] [Citation(s) in RCA: 120] [Impact Index Per Article: 10.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/14/2013] [Revised: 06/28/2013] [Accepted: 07/02/2013] [Indexed: 01/01/2023] Open
Abstract
Epilepsy comprises several syndromes, amongst the most common being mesial temporal lobe epilepsy with hippocampal sclerosis. Seizures in mesial temporal lobe epilepsy with hippocampal sclerosis are typically drug-resistant, and mesial temporal lobe epilepsy with hippocampal sclerosis is frequently associated with important co-morbidities, mandating the search for better understanding and treatment. The cause of mesial temporal lobe epilepsy with hippocampal sclerosis is unknown, but there is an association with childhood febrile seizures. Several rarer epilepsies featuring febrile seizures are caused by mutations in SCN1A, which encodes a brain-expressed sodium channel subunit targeted by many anti-epileptic drugs. We undertook a genome-wide association study in 1018 people with mesial temporal lobe epilepsy with hippocampal sclerosis and 7552 control subjects, with validation in an independent sample set comprising 959 people with mesial temporal lobe epilepsy with hippocampal sclerosis and 3591 control subjects. To dissect out variants related to a history of febrile seizures, we tested cases with mesial temporal lobe epilepsy with hippocampal sclerosis with (overall n = 757) and without (overall n = 803) a history of febrile seizures. Meta-analysis revealed a genome-wide significant association for mesial temporal lobe epilepsy with hippocampal sclerosis with febrile seizures at the sodium channel gene cluster on chromosome 2q24.3 [rs7587026, within an intron of the SCN1A gene, P = 3.36 × 10(-9), odds ratio (A) = 1.42, 95% confidence interval: 1.26-1.59]. In a cohort of 172 individuals with febrile seizures, who did not develop epilepsy during prospective follow-up to age 13 years, and 6456 controls, no association was found for rs7587026 and febrile seizures. These findings suggest SCN1A involvement in a common epilepsy syndrome, give new direction to biological understanding of mesial temporal lobe epilepsy with hippocampal sclerosis with febrile seizures, and open avenues for investigation of prognostic factors and possible prevention of epilepsy in some children with febrile seizures.
Collapse
Affiliation(s)
- Dalia Kasperavičiūtė
- 1 NIHR University College London Hospitals Biomedical Research Centre, Department of Clinical and Experimental Epilepsy, UCL Institute of Neurology, Queen Square, London, WC1N 3BG, UK
| | - Claudia B. Catarino
- 1 NIHR University College London Hospitals Biomedical Research Centre, Department of Clinical and Experimental Epilepsy, UCL Institute of Neurology, Queen Square, London, WC1N 3BG, UK
- 2 Epilepsy Society, Chalfont-St-Peter, SL9 0RJ, UK
| | - Mar Matarin
- 1 NIHR University College London Hospitals Biomedical Research Centre, Department of Clinical and Experimental Epilepsy, UCL Institute of Neurology, Queen Square, London, WC1N 3BG, UK
| | - Costin Leu
- 1 NIHR University College London Hospitals Biomedical Research Centre, Department of Clinical and Experimental Epilepsy, UCL Institute of Neurology, Queen Square, London, WC1N 3BG, UK
| | - Jan Novy
- 1 NIHR University College London Hospitals Biomedical Research Centre, Department of Clinical and Experimental Epilepsy, UCL Institute of Neurology, Queen Square, London, WC1N 3BG, UK
- 2 Epilepsy Society, Chalfont-St-Peter, SL9 0RJ, UK
| | - Anna Tostevin
- 1 NIHR University College London Hospitals Biomedical Research Centre, Department of Clinical and Experimental Epilepsy, UCL Institute of Neurology, Queen Square, London, WC1N 3BG, UK
- 2 Epilepsy Society, Chalfont-St-Peter, SL9 0RJ, UK
| | - Bárbara Leal
- 3 Immunogenetics Laboratory, University of Porto, 4050-313 Porto, Portugal
- 4 UMIB - Instituto Ciências Biomédicas Abel Salazar, University of Porto, 4099-003 Porto, Portugal
| | - Ellen V. S. Hessel
- 5 Rudolf Magnus Institute of Neuroscience, Department of Neuroscience and Pharmacology, University Medical Centre Utrecht, 3584 CG Utrecht, The Netherlands
| | - Kerstin Hallmann
- 6 Department of Epileptology, University of Bonn, 53105 Bonn, Germany
- 7 Life & Brain Centre, University of Bonn, 53105 Bonn, Germany
| | - Michael S. Hildebrand
- 8 Epilepsy Research Centre, Austin Health, University of Melbourne, Melbourne VIC 3084, Australia
| | - Hans-Henrik M. Dahl
- 8 Epilepsy Research Centre, Austin Health, University of Melbourne, Melbourne VIC 3084, Australia
| | - Mina Ryten
- 9 Department of Molecular Neuroscience, UCL Institute of Neurology, London, WC1N 3BG, UK
- 10 Reta Lila Weston Institute, UCL Institute of Neurology, London, WC1N 3BG, UK
| | - Daniah Trabzuni
- 9 Department of Molecular Neuroscience, UCL Institute of Neurology, London, WC1N 3BG, UK
- 10 Reta Lila Weston Institute, UCL Institute of Neurology, London, WC1N 3BG, UK
- 11 Department of Genetics, King Faisal Specialist Hospital and Research Centre, Riyadh, 11211, Saudi Arabia
| | - Adaikalavan Ramasamy
- 9 Department of Molecular Neuroscience, UCL Institute of Neurology, London, WC1N 3BG, UK
- 10 Reta Lila Weston Institute, UCL Institute of Neurology, London, WC1N 3BG, UK
- 12 Department of Medical and Molecular Genetics, King’s College London, Guy's Hospital, London, SE1 9RT, UK
| | - Saud Alhusaini
- 13 Molecular and Cellular Therapeutics Department, Royal College of Surgeons in Ireland, Dublin 2, Ireland
- 14 Brain Morphometry Laboratory, Neurophysics Department, Beaumont Hospital, Dublin 9, Ireland
| | - Colin P. Doherty
- 15 Department of Neurology, St James’ Hospital, Dublin 8, Ireland
| | - Thomas Dorn
- 16 Swiss Epilepsy Centre, 8008 Zurich, Switzerland
| | - Jörg Hansen
- 16 Swiss Epilepsy Centre, 8008 Zurich, Switzerland
| | | | | | - Dominik Zumsteg
- 18 Department of Neurology, University Hospital Zurich, 8091 Zurich, Switzerland
| | - Susan Duncan
- 19 Edinburgh and South East Scotland Epilepsy Service, Western General Hospital Edinburgh, EH4 2XU, Scotland, UK
| | - Reetta K. Kälviäinen
- 20 Kuopio Epilepsy Centre, Kuopio University Hospital, 70211 Kuopio, Finland
- 21 Department of Neurology, Institute of Clinical Medicine, University of Eastern Finland, 70211 Kuopio, Finland
| | - Kai J. Eriksson
- 22 Paediatric Neurology Unit, Tampere University Hospital and Paediatric Research Centre, University of Tampere, 33521 Tampere, Finland
| | - Anne-Mari Kantanen
- 20 Kuopio Epilepsy Centre, Kuopio University Hospital, 70211 Kuopio, Finland
| | - Massimo Pandolfo
- 23 Department of Neurology, Hôpital Erasme, Université Libre de Bruxelles, 1070 Brussels, Belgium
| | | | - Kurt Schlachter
- 25 Department of Paediatrics, LKH Bregenz, 6900 Bregenz, Austria
| | - Eva M. Reinthaler
- 26 Department of Clinical Neurology, Medical University of Vienna, 1090 Vienna, Austria
| | - Elisabeth Stogmann
- 26 Department of Clinical Neurology, Medical University of Vienna, 1090 Vienna, Austria
| | - Fritz Zimprich
- 26 Department of Clinical Neurology, Medical University of Vienna, 1090 Vienna, Austria
| | - Emilie Théâtre
- 27 Groupe Interdisciplinaire de Génoprotéomique Appliquée (GIGA-R) and Faculty of Veterinary Medicine, University of Liège, 4000 Liège, Belgium
- 28 Unit of Gastroenterology, Centre Hospitalier Universitaire, University of Liège, 4000 Liège, Belgium
| | - Colin Smith
- 29 Department of Neuropathology, MRC Sudden Death Brain Bank Project, University of Edinburgh, Wilkie Building, Edinburgh, EH8 9AG, UK
| | - Terence J. O’Brien
- 30 Departments of Medicine and Neurology, Royal Melbourne Hospital, University of Melbourne, Melbourne VIC 3050, Australia
- 31 Melbourne Brain Centre, University of Melbourne, Melbourne VIC 3084, Australia
| | - K. Meng Tan
- 30 Departments of Medicine and Neurology, Royal Melbourne Hospital, University of Melbourne, Melbourne VIC 3050, Australia
- 31 Melbourne Brain Centre, University of Melbourne, Melbourne VIC 3084, Australia
| | - Slave Petrovski
- 30 Departments of Medicine and Neurology, Royal Melbourne Hospital, University of Melbourne, Melbourne VIC 3050, Australia
- 31 Melbourne Brain Centre, University of Melbourne, Melbourne VIC 3084, Australia
- 32 Department of Medicine, Austin Health, University of Melbourne, Melbourne VIC 3084, Australia
| | - Angela Robbiano
- 33 Department of Neurosciences, Laboratory of Neurogenetics, University of Genoa, ‘G. Gaslini’ Institute, 16147 Genova, Italy
| | - Roberta Paravidino
- 33 Department of Neurosciences, Laboratory of Neurogenetics, University of Genoa, ‘G. Gaslini’ Institute, 16147 Genova, Italy
| | - Federico Zara
- 33 Department of Neurosciences, Laboratory of Neurogenetics, University of Genoa, ‘G. Gaslini’ Institute, 16147 Genova, Italy
| | - Pasquale Striano
- 34 Paediatric Neurology and Muscular Diseases Unit, Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, University of Genoa, ‘G. Gaslini’ Institute, 16147 Genova, Italy
| | - Michael R. Sperling
- 35 Department of Neurology, Thomas Jefferson University, Philadelphia, PA 19107, USA
| | - Russell J. Buono
- 36 Department of Biomedical Science, Cooper Medical School of Rowan University, Camden, NJ 08103, USA
| | - Hakon Hakonarson
- 37 Centre for Applied Genomics, The Children’s Hospital of Philadelphia, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104-4318, USA
| | - João Chaves
- 38 Department of Neurological Disorders and Senses, Hospital Santo António / Centro Hospitalar do Porto, 4099-001 Porto, Portugal
| | - Paulo P. Costa
- 3 Immunogenetics Laboratory, University of Porto, 4050-313 Porto, Portugal
- 4 UMIB - Instituto Ciências Biomédicas Abel Salazar, University of Porto, 4099-003 Porto, Portugal
- 39 Instituto Nacional de Saúde Dr. Ricardo Jorge (INSA), 4049-019 Porto, Portugal
| | - Berta M. Silva
- 3 Immunogenetics Laboratory, University of Porto, 4050-313 Porto, Portugal
- 4 UMIB - Instituto Ciências Biomédicas Abel Salazar, University of Porto, 4099-003 Porto, Portugal
| | - António M. da Silva
- 4 UMIB - Instituto Ciências Biomédicas Abel Salazar, University of Porto, 4099-003 Porto, Portugal
- 38 Department of Neurological Disorders and Senses, Hospital Santo António / Centro Hospitalar do Porto, 4099-001 Porto, Portugal
| | - Pierre N. E. de Graan
- 5 Rudolf Magnus Institute of Neuroscience, Department of Neuroscience and Pharmacology, University Medical Centre Utrecht, 3584 CG Utrecht, The Netherlands
| | - Bobby P. C. Koeleman
- 40 Department of Medical Genetics, University Medical Centre Utrecht, 3584 CG Utrecht, The Netherlands
| | - Albert Becker
- 41 Department of Neuropathology, University of Bonn, 53105 Bonn, Germany
| | - Susanne Schoch
- 41 Department of Neuropathology, University of Bonn, 53105 Bonn, Germany
| | - Marec von Lehe
- 42 Department of Neurosurgery, University of Bochum, 44892 Bochum, Germany
| | - Philipp S. Reif
- 43 Epilepsy-Centre Hessen, Department of Neurology, University Hospitals and Philipps-University Marburg, 35043 Marburg, Germany
| | - Felix Rosenow
- 43 Epilepsy-Centre Hessen, Department of Neurology, University Hospitals and Philipps-University Marburg, 35043 Marburg, Germany
| | - Felicitas Becker
- 44 Department of Neurology and Epileptology, Hertie Institute for Clinical Brain Research, University of Tübingen, 72076 Tübingen, Germany
| | - Yvonne Weber
- 44 Department of Neurology and Epileptology, Hertie Institute for Clinical Brain Research, University of Tübingen, 72076 Tübingen, Germany
| | - Holger Lerche
- 44 Department of Neurology and Epileptology, Hertie Institute for Clinical Brain Research, University of Tübingen, 72076 Tübingen, Germany
| | - Karl Rössler
- 45 Department of Neurosurgery, University Hospital Erlangen, 91054 Erlangen, Germany
| | - Michael Buchfelder
- 45 Department of Neurosurgery, University Hospital Erlangen, 91054 Erlangen, Germany
| | - Hajo M. Hamer
- 46 Department of Neurology, Epilepsy Centre, University Hospital Erlangen, 91054 Erlangen, Germany
| | - Katja Kobow
- 47 Department of Neuropathology, University Hospital Erlangen, 91054 Erlangen, Germany
| | - Roland Coras
- 47 Department of Neuropathology, University Hospital Erlangen, 91054 Erlangen, Germany
| | - Ingmar Blumcke
- 47 Department of Neuropathology, University Hospital Erlangen, 91054 Erlangen, Germany
| | - Ingrid E. Scheffer
- 8 Epilepsy Research Centre, Austin Health, University of Melbourne, Melbourne VIC 3084, Australia
- 48 Florey Institute of Neuroscience and Mental Health, Melbourne VIC 3010, Australia
- 49 Department of Paediatrics, University of Melbourne, Royal Children’s Hospital, Melbourne VIC 3052, Australia
| | - Samuel F. Berkovic
- 8 Epilepsy Research Centre, Austin Health, University of Melbourne, Melbourne VIC 3084, Australia
| | - Michael E. Weale
- 12 Department of Medical and Molecular Genetics, King’s College London, Guy's Hospital, London, SE1 9RT, UK
| | - UK Brain Expression Consortium
- 9 Department of Molecular Neuroscience, UCL Institute of Neurology, London, WC1N 3BG, UK
- 10 Reta Lila Weston Institute, UCL Institute of Neurology, London, WC1N 3BG, UK
| | - Norman Delanty
- 13 Molecular and Cellular Therapeutics Department, Royal College of Surgeons in Ireland, Dublin 2, Ireland
- 50 Department of Neurology, Beaumont Hospital, Dublin 9, Ireland
| | - Chantal Depondt
- 23 Department of Neurology, Hôpital Erasme, Université Libre de Bruxelles, 1070 Brussels, Belgium
| | - Gianpiero L. Cavalleri
- 13 Molecular and Cellular Therapeutics Department, Royal College of Surgeons in Ireland, Dublin 2, Ireland
| | - Wolfram S. Kunz
- 6 Department of Epileptology, University of Bonn, 53105 Bonn, Germany
- 7 Life & Brain Centre, University of Bonn, 53105 Bonn, Germany
| | - Sanjay M. Sisodiya
- 1 NIHR University College London Hospitals Biomedical Research Centre, Department of Clinical and Experimental Epilepsy, UCL Institute of Neurology, Queen Square, London, WC1N 3BG, UK
- 2 Epilepsy Society, Chalfont-St-Peter, SL9 0RJ, UK
| |
Collapse
|
22
|
Hessel EVS, van Lith HA, Wolterink-Donselaar IG, de Wit M, Hendrickx DAE, Kas MJH, de Graan PNE. Mapping an X-linked locus that influences heat-induced febrile seizures in mice. Epilepsia 2012; 53:1399-410. [PMID: 22780306 DOI: 10.1111/j.1528-1167.2012.03575.x] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/10/2023]
Abstract
PURPOSE Febrile seizures (FS) are the most common seizure type in children between the age of 6 months and 5 years. Although FS are largely benign, recurrent FS are a major risk factor for developing temporal lobe epilepsy (TLE) later in life. The mechanisms underlying FS are largely unknown; however, family and twin studies indicate that FS susceptibility is under complex genetic control. We have recently developed a phenotypic screen to study the genetics of FS susceptibility in mice. Using this screen in a phenotype-driven genetic strategy we analyzed the C57BL/6J-Chr #(A)/NaJ chromosome substitution strain (CSS) panel. In each CSS line one chromosome of the A/J strain is substituted in a genetically homogeneous C57BL/6J background. The analysis of the CSS panel revealed that A/J chromosomes 1, 2, 6, 10, 13, and X carry at least one quantitative trait locus (QTL) for heat-induced FS susceptibility. The fact that many X-linked genes are highly expressed in the brain and have been implicated in human developmental disorders often presenting with seizures (like fragile X mental retardation) prompted us to map the chromosome X QTL. METHODS C57BL/6J mice were mated with C57BL/6J-Chr X(A) /NaJ (CSSX) to generate F(2)-generations-CXBL6 and BL6CX-originating from CSSX or C57BL/6J mothers, respectively. Heat-induced FS were elicited on postnatal day 14 by exposure to a controlled warm airstream of 50°C. The latency to heat-induced FS is our phenotype. This phenotype has previously been validated by video-electroencephalography (EEG) monitoring. After phenotyping and genotyping the F(2)-population, QTL analysis was performed using R/QTL software. KEY FINDINGS QTL analysis revealed a significant peak with an LOD-score of 3.25. The 1-LOD confidence interval (149,886,866-158,836,462 bp) comprises 52 protein coding genes, of which 34 are known to be brain expressed. Two of these brain-expressed genes have previously been linked to X-linked epilepsies, namely Cdkl5 and Pdha1. SIGNIFICANCE Our results show that the mouse genetics of X-linked FS susceptibility is complex, and that our heat-induced FS-driven genetic approach is a powerful tool for use in unraveling the complexities of this trait in mice. Fine-mapping and functional studies will be required to further identify the X-linked FS susceptibility genes.
Collapse
Affiliation(s)
- Ellen V S Hessel
- Rudolf Magnus Institute of Neuroscience, Department of Neuroscience and Pharmacology, University Medical Center Utrecht, Utrecht, The Netherlands
| | | | | | | | | | | | | |
Collapse
|
23
|
Alkemade A, Unmehopa UA, Hessel EVS, Swaab DF, Kalsbeek A, Fliers E. Suppressor of cytokine signaling 3 in the human hypothalamus. Peptides 2012; 35:139-42. [PMID: 22425648 DOI: 10.1016/j.peptides.2012.03.004] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/04/2012] [Revised: 03/07/2012] [Accepted: 03/07/2012] [Indexed: 10/28/2022]
Abstract
In rodents, the mediobasal hypothalamus and the hypothalamic paraventricular nucleus (PVN) are implicated in leptin signaling. Surprisingly little data is available on the human hypothalamus. We set out to study the expression of suppressor-of-cytokine-signaling 3 (SOCS3), α-melanocyte stimulating hormone (αMSH) and agouti-related protein (AgRP) in the infundibular nucleus (IFN) and to investigate the relationship between these neuropeptide expressions and serum leptin concentrations in a blood sample taken within 24h before death. We studied post-mortem human brain material by means of quantitative immunocytochemistry. We found that SOCS3 immunoreactivity was widely distributed throughout the hypothalamus, and most prominent in the PVN, whereas expression levels in the IFN were low. Surprisingly, SOCS3 expression in the PVN was inversely related to serum leptin. A significant positive correlation was observed between AgRP and NPY expression in the IFN. The inverse correlation between SOCS3 expression in the PVN and serum leptin was unexpected and may be related to the hypothalamic adaptation to fatal illness rather than to nutritional status, or may represent an interspecies difference.
Collapse
Affiliation(s)
- Anneke Alkemade
- Netherlands Institute for Neuroscience, An Institute of the Royal Netherlands Academy of Arts and Science, Amsterdam, The Netherlands.
| | | | | | | | | | | |
Collapse
|
24
|
Kan AA, van Erp S, Derijck AAHA, de Wit M, Hessel EVS, O'Duibhir E, de Jager W, Van Rijen PC, Gosselaar PH, de Graan PNE, Pasterkamp RJ. Genome-wide microRNA profiling of human temporal lobe epilepsy identifies modulators of the immune response. Cell Mol Life Sci 2012; 69:3127-45. [PMID: 22535415 PMCID: PMC3428527 DOI: 10.1007/s00018-012-0992-7] [Citation(s) in RCA: 147] [Impact Index Per Article: 12.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/01/2012] [Revised: 03/22/2012] [Accepted: 04/02/2012] [Indexed: 10/28/2022]
Abstract
Mesial temporal lobe epilepsy (mTLE) is a chronic neurological disorder characterized by recurrent seizures. The pathogenic mechanisms underlying mTLE may involve defects in the post-transcriptional regulation of gene expression. MicroRNAs (miRNAs) are non-coding RNAs that control the expression of genes at the post-transcriptional level. Here, we performed a genome-wide miRNA profiling study to examine whether miRNA-mediated mechanisms are affected in human mTLE. miRNA profiles of the hippocampus of autopsy control patients and two mTLE patient groups were compared. This revealed segregated miRNA signatures for the three different patient groups and 165 miRNAs with up- or down-regulated expression in mTLE. miRNA in situ hybridization detected cell type-specific changes in miRNA expression and an abnormal nuclear localization of select miRNAs in neurons and glial cells of mTLE patients. Of several cellular processes implicated in mTLE, the immune response was most prominently targeted by deregulated miRNAs. Enhanced expression of inflammatory mediators was paralleled by a reduction in miRNAs that were found to target the 3'-untranslated regions of these genes in reporter assays. miR-221 and miR-222 were shown to regulate endogenous ICAM1 expression and were selectively co-expressed with ICAM1 in astrocytes in mTLE patients. Our findings suggest that miRNA changes in mTLE affect the expression of immunomodulatory proteins thereby further facilitating the immune response. This mechanism may have broad implications given the central role of astrocytes and the immune system in human neurological disease. Overall, this work extends the current concepts of human mTLE pathogenesis to the level of miRNA-mediated gene regulation.
Collapse
Affiliation(s)
- Anne A Kan
- Department of Neuroscience and Pharmacology, University Medical Center Utrecht, Universiteitsweg 100, 3584 CG, Utrecht, The Netherlands
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
25
|
van Gassen KLI, Hessel EVS, Ramakers GMJ, Notenboom RGE, Wolterink-Donselaar IG, Brakkee JH, Godschalk TC, Qiao X, Spruijt BM, van Nieuwenhuizen O, de Graan PNE. Characterization of febrile seizures and febrile seizure susceptibility in mouse inbred strains. Genes Brain Behav 2008; 7:578-86. [PMID: 18363854 DOI: 10.1111/j.1601-183x.2008.00393.x] [Citation(s) in RCA: 39] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Abstract
Febrile seizures (FS) are the most prevalent seizures in children. Although FS are largely benign, complex FS increase the risk to develop temporal lobe epilepsy (TLE). Studies in rat models for FS have provided information about functional changes in the hippocampus after complex FS. However, our knowledge about the genes and pathways involved in the causes and consequences of FS is still limited. To enable molecular, genetic and knockout studies, we developed and characterized an FS model in mice and used it as a phenotypic screen to analyze FS susceptibility. Hyperthermia was induced by warm air in 10- to 14-day-old mice and induced FS in all animals. Under the conditions used, seizure-induced behavior in mice and rats was similar. In adulthood, treated mice showed increased hippocampal Ih current and seizure susceptibility, characteristics also seen after FS in rats. Of the seven genetically diverse mouse strains screened for FS susceptibility, C57BL/6J mice were among the most susceptible, whereas A/J mice were among the most resistant. Strains genetically similar to C57BL/6J also showed a susceptible phenotype. Our phenotypic data suggest that complex genetics underlie FS susceptibility and show that the C57BL/6J strain is highly susceptible to FS. As this strain has been described as resistant to convulsants, our data indicate that susceptibility genes for FS and convulsants are distinct. Insight into the mechanisms underlying seizure susceptibility and FS may help to identify markers for the early diagnosis of children at risk for complex FS and TLE and may provide new leads for treatment.
Collapse
Affiliation(s)
- K L I van Gassen
- Department of Neuroscience and Pharmacology, Rudolf Magnus Institute of Neuroscience, University Medical Center Utrecht, Utrecht, The Netherlands
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|